Author(s): Trine Alma Knudsen, Dennis Lund Hansen, Lukas Frans Ocias, et al. Abstract: S131 Session topic: 16. Myeloproliferative neoplasms – Clinical Background Hydroxyurea (HU) is considered first line cytoreductive therapy in most parts of the world for patients with Myeloproliferative Neoplasms (MPNs). The drug effectively lowers the risk of thrombosis but there...
Pro zobrazení tohoto obsahu je třeba být přihlášen.